[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hugh Taylor\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100465657","early-phase-1-bone-marrow-derived-stem-cells-mobilization-for-treatment-of-abnormal-endometrium-100465657",false,"NCT05343572","Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium","Bone Marrow Derived Stem Cells Mobilization for Treatment of Asherman's Syndrome, Atrophic Endometrium, and Recurrent Implantation Failure","Inclusion Criteria:\n\n* Healthy, non pregnant females\n* ages ≥18 and ≤40 years old at time of enrollment\n* with either AS, AE, or RIF\n\n  1. For AS: surgical history of intrauterine trauma\u002Finfection, hypo\u002Famenorrhea, intra-uterine adhesions\n  2. for AE: US documentation of persistent, \\\u003C6mm endometrial thickness\n  3. for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic\n\nExclusion Criteria:\n\n* Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)\n* Endometriosis (diagnosed by previous surgery,)\n* Diminished ovarian reserve (AMH\\\u003C1ng\u002Fml or follicle stimulating hormone (FSH)\\>10)\n* History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly\n* Submucous or intracavitary fibroid, polyps\n* Currently pregnant\n* Personal history of thrombophilia or sickle cell disease\n* Inability to provide informed consent",true,"FEMALE","18 Years","40 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\\[1,4-phenylenebis-(methylene)\\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).",[28,29,30],"Asherman Syndrome","Atrophic Endometrium","Recurrent Implantation Failure",[32],"bone marrow derived stem cells","RECRUITING","2025-11-07",{"date":36,"type":37},"2025-11-12","ACTUAL",{"date":39,"type":37},"2023-11-01",{"date":41,"type":22},"2027-12",{"name":43,"class":44},"Hugh Taylor","OTHER",""]